Guidance Document: Reconsideration of Decisions Issued for Human Drug and Natural Health Product Submissions
Related Services
Related acts and regulations
Overview
When Health Canada issues certain negative decisions related to the submission review process for a human drug, including hard-surface disinfectants, or a natural health product, the applicant may request a reconsideration of the decision. This document provides Guidance regarding the process. This document replaces the guidance, “Reconsideration of Decisions Issued for Human Drug Submissions,” issued 2015/04/01.Who this guide is for
Applicants and Sponsors with submissions to Therapeutic Products Directorate, Biologics and Genetic Therapies Directorate, Natural and Non-prescription Health Products Directorate, as well as regulatory staff from these directorates.
In this guide
- 1.0 Overview
- 2.0 Decisions Eligible for Reconsideration
- 3.0 Possible Outcomes of a Request for Reconsideration
- 4.0 The Reconsideration Process
- 4.1 Overview
- 4.2 Detailed Outline of Reconsideration Process
- 4.2.1 Letter of Intent
- 4.2.2 Request for Reconsideration
- 4.2.3 Decision Regarding Process Path
- 4.2.4 Internal Review
- 4.2.5 External Reconsideration Panel
- 4.2.6 The Reconsideration Meeting
- 4.2.7 Making Recommendations to the Director General
- 4.2.8 Decision by the Director General
- 4.2.9 Follow-up Action
- 5.0 Roles and Responsibilities
- 6.0 Information Formats and Address
- 6.1 Human Drugs
- 6.2 Natural Health Products
- Appendix A: Reconsideration Process Map
- Appendix B: Performance Targets
- Appendix C: Request for Human Drugs Reconsideration Template
- Appendix D: Request for Natural Health Products Reconsideration Template
Details and history
Published: November 30, 2015
Updated: September 4, 2026
Consulted: June 27, 2018
For assistance
Contact the Food and Drugs Act Liaison Office (FDALO) if you need assistance:
Contact us by phone:
Toll Free: 1-866-339-4998
Telephone: 613-957-4284
Contact us by email:
fdalo@hc-sc.gc.ca
Service standards: We answer e-mail and telephone messages within 1 business day.
For more information about the Food and Drugs Act Liaison Office (FDALO) and services, please visit our webpage at http://www.healthcanada.gc.ca/fdalo
